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Some information, however, can be gleaned from the re-
sults reported inourstudy.First, themedian(interquartile range
[IQR]) serum testosterone level in our treated cohort during
follow-upwas318(237-435)ng/dLcomparedwiththeuntreated
population with amedian (IQR) 212 (160-253) ng/dL; testoste-
rone replacement therapy resulted in a significant increase in
serum levels with over half of the patients normalizing their
serumtestosterone levels. Second, althoughwedidnot gener-
ate a FraminghamRisk Score for the patients in our study,1 we
did conduct a stratified analysis restricted to men with base-
line cardiovascular risk factors and the results from this strati-
fied analysis were consistent with our overall study findings.
Third,wehave seen thebeneficial effects of treatinghyperten-
sion or hyperlipidemia in our population in recent years,3
suggesting that this couldaffect our results. Thus,we included
calendar year in our adjustedmodels and found a lower risk of
cardiovascular outcomes over time potentially related to
changing treatment patterns and/or length of follow-up.
We believe the questions posed by Stavropoulos and
colleagues probe important nuances about the potential
relationship between testosterone replacement therapy
and cardiovascular disease outcomes. Undoubtedly, further
focused studies based in other cohorts ofmen, fromdifferent
settings, could provide important new insights.
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Redefining UnexplainedAnemia in Elderly
To the Editor The Original Investigation by Roy et al1 recently
published in JAMA Internal Medicine showed in a well-
executeddouble-blindplacebo-controlled trial the efficacyof
testosterone supplementation in correcting anemia among
oldermenwith low testosterone concentrations. The authors
concluded that testosterone supplementation is a feasible
approach to increase hemoglobin levels of both unexplained
anemiaaswell as anemia fromknowncauses.Theauthors first
defined known causes of anemia by choosing specific cut-off
values and subsequently categorized the remaining group of
patients as having an unexplained anemia. However, regard-
ing 2 known causes of anemia, we question whether the
authors did not underestimate its prevalence.
First, to define iron deficiency, Roy et al1 used a serum
ferritin level of lower than 40 ng/mL. However, it has been
established2 that iron deficient erythropoiesis occurs in
elderly patients with a serum ferritin level of up to 75 ng/mL,
which is nearly the double of the currently chosen cut-off
value. Therefore, a portion of the patients currently labeled
as having an unexplained anemia can still be classified as
being iron deficient.
Second, to define vitamin B12 deficiency Roy et al1
selected all patients with a vitamin B12 level of lower than
200 pg/mL. Yet, it should be realized that serum levels of
vitamin B12 are maintained for a long time at the expense of
vitamin B12 stores. As a result, diagnosis of vitamin B12 defi-
ciency is often delayed and underestimated. Hence, the im-
portantFraminghamstudy3useda cut-off valueof 350pg/mL
to define vitamin B12 deficiency in elderly patients which is
more realistic to fully capture vitamin B12 deficiency.
Subanalyses in which these cut-off values for iron defi-
ciency and vitamin B12 deficiency, both highly prevalent in
elderly populations, are taken into account could potentially
further strengthen the reported results by Roy et al.1 Finally,
we would like to mention that the beneficial effect of cor-
recting unexplained anemia through testosterone supple-
mentation might be attributable to down-regulation of
serum hepcidin, the master regulator of iron homeostasis.
Previous studies have revealed that elderly with an unex-
plained anemia have elevated levels of serum hepcidin.4
Because testosterone is known to be a prominent suppressor
of serum hepcidin,5 it is likely that serum hepcidin will
decrease, and subsequently, iron availability will improve
and lead to a more effective erythropoiesis. Future studies
evaluating the effect of testosterone supplementation on
hemoglobin levels might want to consider measuring serum
hepcidin as putative mechanism.
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In Reply We appreciate the comments of Eisenga et al
regarding our classification of the anemias in our Original
Investigation.1 They question our choices of the levels of
ferritin and B12 used to classify patients as iron-deficient or
Vitamin B12–deficient, respectively. Their questions raise the
more general issue that there is no universally accepted
cut-off level by which either anemia can be diagnosed
using a single test. We concede that wemight havemisclassi-
fied a few participants in either direction for each type of
anemia.
With respect to iron deficiency, others have suggested
that ferritin values in the general range we selected
(<40 ng/mL) are reasonable for a presumptive diagnosis of
iron deficiency anemia.2 Indeed in the study cited by Eisenga
et al,3 ferritin levels 45 to 75 ng/mL were suspected to be
related to iron deficiency only on the basis of blood film
evaluation, not the demonstration of absent iron stores, as
was the case for those with levels less than 45 ng/mL. Even
some patients whose levels were less than 45 ng/mL had iron
stores present. Thus misclassification may occur in either
direction. Similarly, B12 levels have limited sensitivity and
specificity, and while a value of less than 200 ng/L more
likely indicates true deficiency than higher levels, some indi-
viduals whose values are greater than 200 ng/L could have
relative B12 deficiency.4,5 Whether this mild deficiency would
be sufficient to cause anemia is uncertain.
Nevertheless,while somedegreeofmisclassificationmay
haveoccurred, because testosterone treatment correctedane-
miasof“known”causeaswell asunexplainedanemia,ourcon-
clusion that testosterone improves both types of anemia in
older men who have low testosterone appears solid. We em-
phasize that this conclusionappliesonly tooldermenwith low
testosterone andnot tomenwho are anemic but have normal
testosterone.
With respect to the suggestion by Eisenga et al regarding
the mechanism by which testosterone increased hemoglo-
bin, we agree that testosterone may have acted by suppress-
ing hepcidin.6
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Intensive Blood Pressure Control on Gait Speed
andMobility Limitation for Older Adults
To the Editor In the SPRINT (Systolic Blood Pressure Inter-
vention Trial) randomized clinical trial published in a recent
issue of JAMA Internal Medicine, Odden and colleagues1
conclude that intensive blood pressure lowering was not
associated with changes in gait speed or transitions in
mobility status among adults 75 years or older. SPRINT1 is
an important randomized clinical trial that should have a
substantial influence on future clinical practice. However, it
was not well designed to test the effect of intensive blood
pressure control on gait speed and mobility limitation in
older adults.
First, according to the registration (NCT02106234), the
main outcomes (gait speed and mobility limitation) of this
article were not prespecified, because none of them were
submitted in the registration. This limitation can lead to a
selective outcome of the authors’ intervention.
Second, the sample of older people in SPRINT1maynot be
representative of the general older population.Oddenet al ac-
knowledged that SPRINT excluded individuals with a history
of diabetes or stroke, symptomatic heart failure, dementia, or
an indication for specific antihypertensives. But these comor-
bidities have apopulationprevalence in elderly patients,with
rates that continue to increase.2,3 Additionally, the only
ambulatory, community-basedpersonswere recruited into the
study.1 Therefore, the results do not generalize tomany older
people with multiple coexisting conditions, frailty, and
disabilities.
Third, it is also important to note that no information
was provided about functional limitations, cognitive impair-
ment, hearing or visual problems, and balance or postural
disorders between the groups. These are generalizable to the
older population, but may render the gait speed test more
time-consuming than expected, representing a possible
bias.4
Fourth, the authors didnot report adverse events in older
patients between the intervention and control groups. In the
original SPRINT,5 serious adverse drug events occurredmore
frequently in the aggressively treated group,with an increase
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